Bio


Dr. Wilson Captein is a fellowship-trained psychologist with Stanford Health Care. He is also a clinical associate professor in the Department of Psychiatry and Behavioral Sciences at Stanford University School of Medicine.

Dr. Captein specializes in cognitive behavioral therapy (CBT), acceptance and commitment therapy (ACT), and exposure and response prevention (ERP). He adapts these therapies for patients with autism, attention-deficit/hyperactivity disorder (ADHD), obsessive-compulsive disorder (OCD), and related disorders. He also tailors these treatment modalities to patients in the LGBTQ+ community by focusing on the impact of minority stress. Across all treatment modalities, he emphasizes compassion-focused therapy that prioritizes the therapeutic relationship via transparency, genuineness, and a non-hierarchical, collaborative dynamic.

Dr. Captein’s research interests include sexual identity, sexual health, and alternative sexualities. He has presented to peers at national and international conferences, including annual meetings for the Society for Sex Therapy and Research, the Society for Personality and Social Psychology, and the Midwestern Psychological Association.

Clinical Focus


  • Clinical Psychology

Academic Appointments


  • Clinical Assistant Professor, Psychiatry and Behavioral Sciences

Honors & Awards


  • Graduate Teaching Assistant of the Year, University of Vermont
  • Phi Beta Kappa Honors Society, Kenyon College
  • Ronald Suiter Prize, University of Vermont

Professional Education


  • Fellowship: Stanford University Adult Psychology Postdoctoral Fellowship (2025) CA
  • Internship: San Jose State University (2024)
  • PhD Training: University of Vermont (2024) VT United States of America

All Publications


  • Limited proteolysis–mass spectrometry reveals aging-associated changes in cerebrospinal fluid protein abundances and structures Nature Aging Shuken, S. R., Rutledge, J., Iram, T., Moran Losada, P., Wilson, E. N., Andreasson, K. I., Leib, R. D., Wyss-Coray, T. 2022
  • Characteristics of Patients With Complex Limb Pain Evaluated Through an Interdisciplinary Approach Utilizing Magnetic Resonance Neurography Frontiers in Pain Research Johnson, E. M., Yoon, D., Biswal, S., Curtin, C., Fox, P., Wilson, T. J., Carroll, I., Lutz, A., Tawfik, V. 2021
  • Proinflammatory IgG Fc structures in patients with severe COVID-19 Nature Immunology Chakraborty, S., Gonzales, J., Edwards, K., Mallajosyulla, V., Buzzanco, A. S., Sherwood, R., Buffone, C., Kathale, N., Providenza, S., Xie, M. M., Andrews, J. R., Blish, C. A., Singh, U., Dugan, H., Wilson, P. C., Pham, T. D., Boyd, S. D., Nadeau, K. C., Pinsky, B. A., Zhang, S., Memoli, M. J., Taubenberger, J. K., Morales, T., Schapiro, J. M., Tan, G. S., et al 2020
  • Peripheral TREM1 responses to brain and intestinal immunogens amplify stroke severity Nature Immunology Liu, Q., Johnson, E., et al 2019
  • Controlling cell shape on hydrogels using lift-off protein patterning PLoS ONE Moeller, J., Denisin, A. K., Sim, J., Wilson, R. E., Ribeiro, A. J., Pruitt, B. L. 2018; 13 (1): e0189901

    Abstract

    Polyacrylamide gels functionalized with extracellular matrix proteins are commonly used as cell culture platforms to evaluate the combined effects of extracellular matrix composition, cell geometry and substrate rigidity on cell physiology. For this purpose, protein transfer onto the surface of polyacrylamide hydrogels must result in geometrically well-resolved micropatterns with homogeneous protein distribution. Yet the outcomes of micropatterning methods have not been pairwise evaluated against these criteria. We report a high-fidelity photoresist lift-off patterning method to pattern ECM proteins on polyacrylamide hydrogels with elastic moduli ranging from 5 to 25 kPa. We directly compare the protein transfer efficiency and pattern geometrical accuracy of this protocol to the widely used microcontact printing method. Lift-off patterning achieves higher protein transfer efficiency, increases pattern accuracy, increases pattern yield, and reduces variability of these factors within arrays of patterns as it bypasses the drying and transfer steps of microcontact printing. We demonstrate that lift-off patterned hydrogels successfully control cell size and shape and enable long-term imaging of actin intracellular structure and lamellipodia dynamics when we culture epithelial cells on these substrates.

    View details for DOI 10.1371/journal.pone.0189901

    View details for PubMedCentralID PMC5752030

  • CARE Scale - 7: Development and preliminary validation of a measure assessing factors that impact self-care in chronic pain Clin J Pain Ziadni, M., You, S., Wilson, A., Darnall, B. 2018; March
  • A re-engineered interface and workflow for the open source SimVascular cardiovascular modeling package A re-engineered interface and workflow for the open source SimVascular cardiovascular modeling package Lan, H., Updegrove, A., Wilson, N., Maher, G., Shadden, S., Marsden, A. 2018; 140 (2): 024501-024501-11

    Abstract

    Patient-specific simulation plays an important role in cardiovascular disease research, diagnosis, surgical planning and medical device design, as well as education in cardiovascular biomechanics. simvascular is an open-source software package encompassing an entire cardiovascular modeling and simulation pipeline from image segmentation, three-dimensional (3D) solid modeling, and mesh generation, to patient-specific simulation and analysis. SimVascular is widely used for cardiovascular basic science and clinical research as well as education, following increased adoption by users and development of a GATEWAY web portal to facilitate educational access. Initial efforts of the project focused on replacing commercial packages with open-source alternatives and adding increased functionality for multiscale modeling, fluid-structure interaction (FSI), and solid modeling operations. In this paper, we introduce a major SimVascular (SV) release that includes a new graphical user interface (GUI) designed to improve user experience. Additional improvements include enhanced data/project management, interactive tools to facilitate user interaction, new boundary condition (BC) functionality, plug-in mechanism to increase modularity, a new 3D segmentation tool, and new computer-aided design (CAD)-based solid modeling capabilities. Here, we focus on major changes to the software platform and outline features added in this new release. We also briefly describe our recent experiences using SimVascular in the classroom for bioengineering education.

    View details for DOI 10.1115/1.4038751

    View details for PubMedCentralID PMC5816252

  • Cardiovascular adverse events in the drug-development program of bupropion for smoking cessation: A systematic retrospective adjudication effort. Clin Cardiol. 2017 Jun 12. Kittle, J., et al 2017: 899–906

    Abstract

    In 2011, the US Food and Drug Administration requested that GlaxoSmithKline perform retrospective adjudication of cardiovascular (CV) events reported in the bupropion drug-development trials for smoking cessation.Retrospective adjudication of clinical trial data will not increase the identification of adverse events.We performed a comprehensive retrospective analysis of adverse events in 19 previously completed controlled US clinical trials of bupropion marketed for the treatment of smoking cessation, yielding 9479 subjects (5290 bupropion, 2927 placebo, 1018 active control [ACT], and 244 treated concurrently with bupropion and ACT). All adverse events were sent to the Duke Clinical Research Institute for adjudication by Clinical Events Classification (CEC) physician reviewers. The primary endpoint was a composite of major adverse CV events: CV death, nonfatal myocardial infarction (MI), and nonfatal stroke.Overall, 416 nonfatal CV events in 366 subjects, and 22 deaths, were identified and processed for adjudication. Of these, 7 nonfatal MIs (4 bupropion, 3 placebo, 0 ACT), 5 nonfatal strokes (1 bupropion, 3 placebo, 1 ACT), and 9 CV deaths (4 bupropion, 4 placebo, 1 ACT) were confirmed by the CEC Committee. The primary endpoint occurred in 3/4297 (0.07%) subjects in the bupropion group and in 4/2927 (0.14%) subjects in the placebo group (log-rank P value: 0.613).CV events in bupropion clinical trials for smoking cessation were uncommon, with no observed increase among subjects assigned to bupropion vs placebo. However, this effort was limited by a paucity of quality data.

    View details for DOI 10.1002/clc.22744